➡️Camzyos (mavacamten) Capsules

Company: Bristol-Myers Squibb Company
Date of Approval: April 28, 2022
Treatment for: Hypertrophic Cardiomyopathy

Camzyos (mavacamten) is a first-in-class cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

https://news.1rj.ru/str/ppdprogram

➡️Cuvrior (trientine tetrahydrochloride) Tablets

Company: Orphalan SA
Date of Approval: April 28, 2022
Treatment for: Wilson's Disease

Cuvrior (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.

https://news.1rj.ru/str/ppdprogram

➡️Vivjoa (oteseconazole) Capsules

Company: Mycovia Pharmaceuticals, Inc.
Date of Approval: April 26, 2022
Treatment for: Vaginal Yeast Infection

Vivjoa (oteseconazole) is an oral azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

https://news.1rj.ru/str/ppdprogram

➡️Epsolay (benzoyl peroxide) Cream

Company: Sol-Gel Technologies, Ltd.
Date of Approval: April 22, 2022
Treatment for: Rosacea

Epsolay (benzoyl peroxide) is a topical oxidizing agent for the treatment of inflammatory lesions of rosacea in adults.

https://news.1rj.ru/str/ppdprogram

➡️Alymsys (bevacizumab-maly) Injection

Company: Amneal Pharmaceuticals LLC
Date of Approval: April 13, 2022
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Alymsys (bevacizumab-maly) is a vascular endothelial growth factor inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

https://news.1rj.ru/str/ppdprogram

➡️Vijoice (alpelisib) Tablets

Company: Novartis Pharmaceuticals Corporation
Date of Approval: April 5, 2022
Treatment for: PIK3CA-Related Overgrowth Spectrum

Vijoice (alpelisib) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

https://news.1rj.ru/str/ppdprogram

➡️Igalmi (dexmedetomidine) Sublingual Film

Company: BioXcel Therapeutics, Inc.
Date of Approval: April 5, 2022
Treatment for: Agitation

Igalmi (dexmedetomidine) is a sublingual film formulation of the approved alpha2-adrenergic receptor agonist dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

https://news.1rj.ru/str/ppdprogram

➡️Norliqva (amlodipine besylate) Oral Solution

Date of Approval: February 24, 2022
Company: CMP Pharma, Inc.
Treatment for: High Blood Pressure, Coronary Artery Disease, Angina

Norliqva (amlodipine besylate) is an oral solution formulation of the approved calcium channel blocker amlodipine for the treatment of hypertension and angina in patients with coronary artery disease.

https://news.1rj.ru/str/ppdprogram

➡️Releuko (filgrastim-ayow) Injection

Date of Approval: February 25, 2022
Company: Kashiv BioSciences, LLC
Treatment for: Neutropenia Associated with Chemotherapy, Neutropenia

Releuko (filgrastim-ayow) is a recombinant human granulocyte colony-stimulating factor biosimilar to Neupogen indicated for the treatment of neutropenia associated with chemotherapy and related conditions.

https://news.1rj.ru/str/ppdprogram

➡️Carvykti (ciltacabtagene autoleucel) Suspension for Intravenous Infusion

Date of Approval: February 28, 2022
Company: Janssen Pharmaceutical Companies
Treatment for: Multiple Myeloma

Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.

https://news.1rj.ru/str/ppdprogram

➡️Pyrukynd (mitapivat) Tablets

Date of Approval: February 17, 2022
Company: Agios Pharmaceuticals, Inc.
Treatment for: Pyruvate Kinase Deficiency

Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

https://news.1rj.ru/str/ppdprogram

➡️Vonjo (pacritinib) Capsules

Date of Approval: February 28, 2022
Company: CTI BioPharma Corp.
Treatment for: Myelofibrosis

Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia.

https://news.1rj.ru/str/ppdprogram

➡️Spikevax (Moderna COVID-19 Vaccine) (COVID-19 Vaccine, mRNA) Injection - formerly mRNA-1273

Date of Approval: January 31, 2022
Company: Moderna, Inc.
Treatment for: Prevention of COVID-19

Spikevax (COVID-19 Vaccine, mRNA) is an mRNA vaccine indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Ztalmy (ganaxolone) Oral Suspension

Date of Approval: March 18, 2022
Company: Marinus Pharmaceuticals, Inc.
Treatment for: CDKL5 Deficiency Disorder

Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

https://news.1rj.ru/str/ppdprogram

➡️Opdualag (nivolumab and relatlimab-rmbw) Injection

Date of Approval: March 18, 2022
Company: Bristol Myers Squibb
Treatment for: Melanoma

Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.

https://news.1rj.ru/str/ppdprogram

➡️Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection

Date of Approval: March 23, 2022
Company: Novartis
Treatment for: Prostate Cancer

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

https://news.1rj.ru/str/ppdprogram

➡️Hyftor (sirolimus) Topical Gel

Date of Approval: March 22, 2022
Company: Nobelpharma America, LLC
Treatment for: Facial Angiofibroma Associated with Tuberous Sclerosis

Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Nasonex 24HR Allergy (mometasone furoate monohydrate) Nasal Spray

Date of Approval: March 17, 2022
Company: Perrigo Company plc
Treatment for: Allergic Rhinitis

Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies.

https://news.1rj.ru/str/ppdprogram

➡️Zegalogue (dasiglucagon) Injection

Date of Approval: March 22, 2021
Company: Zealand Pharma A/S
Treatment for: Hypoglycemia

Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older.

https://news.1rj.ru/str/ppdprogram

➡️Lybalvi (olanzapine and samidorphan) Tablets

Date of Approval: May 28, 2021
Company: Alkermes plc
Treatment for: Schizophrenia, Bipolar Disorder

Lybalvi (olanzapine and samidorphan) is a combination of an established antipsychotic agent (olanzapine) and a novel μ-opioid receptor antagonist (samidorphan) for the treatment of schizophrenia and bipolar I disorder.

https://news.1rj.ru/str/ppdprogram

➡️Astepro Allergy (azelastine) Nasal Spray

Date of Approval: June 17, 2021
Company: Bayer HealthCare LLC
Treatment for: Allergic Rhinitis

Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

https://news.1rj.ru/str/ppdprogram